He said the government wanted "a minimum of collaborationand cooperation" with other European countries with anautomobile sector and said Sarkozy had already discussed theissue with German Chancellor Angela Merkel earlier this month (Reporting by Emmanuel Jarry; writing by James Mackenzie). (PinkSheets:CCMC) (), a leader in the marketing and development ofautomobile, truck and military camera products, today announced it will be thefeatured guest on the long-running business show: "Your Monies Worth."The company will announce its plans for the year ahead as well as addressquestions from those who are shareholders as well as potential investorsregarding its products and potential in the new year ahead."It is a fact that America and the world is moving into a new era and the cameraand stand developed by this company fits the mold for mobile surveillance. It israre we find a company with a product that pays for itself from the day ofinstallation into a truck or fleet of trucks as does the CruiseCam product,"said Les Barber, show producer."It's a fact, trucks which install the seat camera save 15 and more ininsurance premiums as well as define the truck's hours of operation, whereaboutsand the driver's ability. Speed and direction, savings in fuel, overtime,unauthorized usage and driver's habits are all monitored. This is addedsavings," Barber added."Our tradition on the show is to find companies of interest and promise andallow these companies of limited means an opportunity to shed light onthemselves as well as address questions from shareholders and investors alike,"Barber said."We are pleased to appear on the show and look forward to launching our new linein the months ahead," said Scott Watkins, CEO of CruiseCam International.The actual date and time will be announced at a later date."Your Monies Worth" broadcasts on 1470 AM South Florida as well as other marketsand worldwide on the web at at 7pm Those who wish to submitquestions for Mr.
GeoPharma Announces Settlement of Clarinex(r) (Desloratadine) ANDA PatentLitigation With Schering and SepracorLARGO, Fla., Jan 20, 2009 (GLOBE NEWSWIRE) GeoPharma, Inc. (Nasdaq:GORX)(the "Company") announced today that it has reached agreement with the ScheringCorporation ("Schering"), and Sepracor, Inc. and the University of Massachusetts(collectively, "Sepracor") settling all Hatch-Waxman litigation relating toDesloratadine tablets (5 mg), with the Company receiving a license under allrelevant patents.The agreement provides for potential modification of select terms based oncertain events and developments. The specific financial terms and conditions ofthe agreement have not been disclosed. 6,100,274, 7,214,683 and 7,214,684, contesting that these patentswere either invalid or had not been infringed upon, which resulted in thesubsequent litigation by Schering and Sepracor.Under the terms of the settlement, GeoPharma can commercially launch its genericDesloratadine product, with 6 months marketing co-exclusivity, on July 1, 2012,or earlier in certain circumstances.
The GeoPharma product is pending FDA approval and seeks anAB-rating as equivalent to Schering's Clarinex(r) tablets indicated for thetreatment of seasonal allergic rhinitis and perennial allergic rhinitis.According to IMS Health, U.S. This major milestone for the company validates our strategic genericdrug manufacturing plans and we, along with our exclusive supplier of theDesloratadine active pharmaceutical ingredient, Morepen Laboratories Limited,will be well prepared to take advantage of the opportunity upon the commerciallaunch date."ABOUT GEOPHARMA, INC.:GeoPharma, Inc. is a rapidly growing Bio/Pharma company with a diversifiedbusiness model participating in 3 main market segments: Specialty Pharma,Manufacturing, and Distribution. The Specialty Pharma division specializes inthe formulation of generic drugs for human and veterinary usage and thedevelopment of medical devices used by oncologists and other medicalprofessionals.